Alfonso Tafur: Different Cancer Sites Drive Different Thrombotic Phenotypes
Alfonso Tafur, Vascular Medicine Fellowship Program Director at University of Chicago, Director of Vascular Medicine Department at NorthShore University, shared on LinkedIn:
”For years, many of us have treated cancer-associated thrombosis as if it were a single disease.
The data keep reminding us: it isn’t.
In the RIETE Registry, we looked at 18,000+ cancer patients vs. 88,000 without.
Within 90 days — 2.5× higher recurrent VTE, ~40% higher major bleeding.
But the real signal? Cancer site matters.
Lung and pancreatic drive clot risk. GI and GU drive bleeding risk.
Cancer-associated thrombosis is not one disease.
It is many biologically different thrombotic phenotypes.
Proud to be part of this team working toward precision vascular care.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?